Transasia Bio-Medicals Ltd. is bringing its international hematology range for the first time to the Indian market.
Jammu, May 13: Transasia Bio-Medicals Ltd., India's leading In-vitro Diagnostic (IVD) player and among the leading global players globally focused on emerging markets, today announced that it is bringing its international hematology range for the first time to the Indian market. Backed by European R&D, the three, launched today, range from 5-Part Differential (5PD) to 3-Part Differential (3PD) automated hematology analyzers, reagents, and controls. These next-generation systems include a number of features to help institutions, clinicians and laboratory technologists offer an accurate diagnosis. Manufactured by Erba Lachema (100% owned subsidiary of Transasia) in the Czech Republic, the H360, H560 and ELite 580 hematology analyzers are widely used in the European and global market.
Hematology analyzers are extensively used inpatient and research settings to count and characterize blood cells for disease detection and monitoring. Basic analyzers return a complete blood count (CBC) with a three-part differential white blood cell (WBC) count. Sophisticated analyzers measure cell morphology and can detect small cell populations to diagnose rare blood conditions.
Formally launching the range, Suresh Vazirani, Chairman & Managing Director, Transasia Bio-Medicals Ltd., said, “Today marks a major milestone in our quest to make high-quality diagnostics affordable for the masses in India. The international hematology range that we are introducing in India are comparable to the best in the world but are priced 25% lower in comparison. Which means that the more these equipment penetrate the Indian market, the more affordable and accessible will be such basic tests for the larger population. This really moves the needle on better preventive healthcare in India, over the long-term. It is a proud moment for all of us at Transasia and it is apt that this coincides with Transasia’s 40th-anniversary celebration.”
As per a 2018 Union Ministry of Health and Family Welfare study, India has the largest number of children with Thalassemia major in the world (150,000). There are almost 42 million carriers of b- thalassemia trait. While the prevalence averages 3-4% across India, a higher frequency has been observed in certain communities, such as Sindhis, Punjabis, Gujaratis, Bengalis, Mahars, Kolis, Saraswats, Lohanas, and Gaurs. An estimated 10,000-15,000 babies with thalassemia major are born annually.
In her comments, Mala Vazirani, Executive Director, Transasia Bio-Medicals Ltd., said, “Accepted world-over for their quality, precision and ease-of-operation, the Erba range of Hematology products will bring about an increase in adoption of automated hematology testing among Indian diagnostic labs. The range offers a new wave of high performance and convenience, making it an ideal choice for every lab. It also provides holistic solutions for clinical testing for a general & targeted diagnostic which is an added advantage for the pediatric and geriatric population.
Other unique features include flagging of abnormal samples, RFID, large colored LCD touch screen, customizable reporting formats, ability to connect to a Laboratory Information System (LIS) for result output and the ready-to-use reagents being cyanide free and environment-friendly. By addressing many challenges that labs and pathologists face, Transasia is helping healthcare professionals (HCPs) focus on giving patients the best possible care.”